Learn More
Invitrogen™ CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
Marque: Invitrogen™ 14-1347-95
Description
Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment. Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis, immunohistology staining of frozen tissue sections, and immunohistology staining of paraffin embedded tissue sections. Applications Tested: The ACT35 (ACT-35) antibody has been tested by flow cytometric analysis of 3-day PHA activated human normal human peripheral blood cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.
OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.
Spécification
| CD134 (OX40) | |
| Monoclonal | |
| 0.5 mg/mL | |
| PBS with 0.09% sodium azide; pH 7.2 | |
| P43489 | |
| Tnfrsf4 | |
| Affinity chromatography | |
| RUO | |
| 7293 | |
| 4°C | |
| Liquid |
| Flow Cytometry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin) | |
| ACT35 (ACT-35) | |
| Unconjugated | |
| Tnfrsf4 | |
| ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l | |
| Mouse | |
| 10 mg | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 κ |
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.